大行评级丨大华继显：百济神州有望实现可持续收入增长 评级“买入”

Core Viewpoint - BeiGene is positioned for sustainable revenue growth through the launch of new products, with a revenue target of $5.1 billion to $5.3 billion likely to be achieved [1] Group 1: Revenue Growth and Product Launch - BeiGene's cancer therapy Brukinsa is expected to continue boosting global sales in the coming years due to its best-in-class characteristics and expanding market penetration [1] - The company is entering a new development phase, projected to achieve positive profits and positive free cash flow starting in 2025 [1] Group 2: Operational Efficiency and Rating - BeiGene is anticipated to leverage its global operational platform to enhance operational efficiency and cash generation capabilities [1] - The rating for BeiGene is set at "Buy," with a target price of HKD 252 [1]